Activation of the TGFβ/Smad pathway have been recognized to upregulate numerous proangiogenic factors such as VEGF (Chruścik et al., 2018), FGF-2 (Yang et al., 2008), and TSP-4 (Muppala et al., 2017) in cancers. This evidence concerns the gene FGF2 and cancer.